Intelgenx Corp.

17 patents currently held · Updated Nov 14, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

Ending by 2030

Aug 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 16, 2026
The maintenance fee for Loxapine film oral dosage form (US 11,648,212) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
2 fees due Oct 7 to 16, 2027 · next Oct 7

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,674,479	Sustained-release bupropion and bupropion/mecamylamine tablets In force Term ends Aug 23, 2028 · From the USPTO record	In force	Term ends Aug 23, 2028	From the USPTO record
US 10,610,528	Solid oral film dosage forms and methods for making same In force Term ends Jun 28, 2031 · From the USPTO record	In force	Term ends Jun 28, 2031	From the USPTO record
US 9,717,682	Solid oral film dosage forms and methods for making same In force Term ends Sep 21, 2031 · From the USPTO record	In force	Term ends Sep 21, 2031	From the USPTO record
US 8,735,374	Oral mucoadhesive dosage form In force Term ends Apr 15, 2032 · From the USPTO record	In force	Term ends Apr 15, 2032	From the USPTO record
US 10,272,038	Film dosage form with extended release mucoadhesive particles In force Ends no later than Nov 26, 2034 · From the USPTO record	In force	Ends no later than Nov 26, 2034	From the USPTO record
US 11,957,785	Film dosage form with extended release mucoadhesive particles In force Term ends Oct 10, 2035 · From the USPTO record	In force	Term ends Oct 10, 2035	From the USPTO record
US 12,653,780	Method of Treatment and Device for the Improved Bioavailability of Leukotriene Receptor Antagonists In force Term ends Aug 28, 2036 · Medium confidence	In force	Term ends Aug 28, 2036	Medium confidence
US 9,949,934	Device and method of treating conditions associated with neuroinflammation In force Term ends Oct 20, 2036 · From the USPTO record	In force	Term ends Oct 20, 2036	From the USPTO record
US 10,722,476	Device and method of treating conditions associated with neuroinflammation In force Term ends Oct 24, 2036 · From the USPTO record	In force	Term ends Oct 24, 2036	From the USPTO record
US 11,648,212	Loxapine film oral dosage form In force Term ends Oct 12, 2037 · From the USPTO record	In force	Term ends Oct 12, 2037	From the USPTO record

10 of 17 patents shown.

Pro members see all 17.

Pro members: see all 17 patents

Also on record, not counted in the 17: 1 patent in force now held by others · 4 lapsed for an unpaid fee · 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 2 abandoned · 23 no status recorded

List them